EYPT

MKT CAP:$1B

EyePoint Pharmaceuticals, Inc.

Market Cap

$1B

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Healthcare·Biotechnology·🇺🇸·NASDAQ

Stock Price

$13.84-$3.64 (-20.82%)

Apr 23, 2026

Company Details

EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company provides ILUVIEN, an injectable sus...

CEO

Jay S. Duker

IPO Date

Jan 27, 2005

Website

eyepointpharma.com

Key Metrics TTM

Revenue

$31M

-27.5% YoY

Net Income

-$232M

EPS (Diluted)

-$3.16

Free Cash Flow

-$243M

Revenue / Share

$0.38

Gross Margin

93.4%

Operating Margin

-776.0%

Net Margin

-739.4%

FCF Margin

-775.8%

P/S

36.7x

P/E

—

Earnings Reports

Q1 2026

May 6, 2026

PENDING

FY 2025

Mar 5, 2026

$31M-27.5%EPS -$3.17

Q4 2025

Mar 5, 2026

$620.0K-94.6%EPS -$0.81

Q3 2025

Nov 6, 2025

$966.0K-90.8%EPS -$0.85

Q2 2025

Aug 7, 2025

$5M-43.7%EPS -$0.85

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q1 22	$9M	$8M	-$18M
Q2 22	$12M	$10M	-$19M
Q3 22	$10M	$9M	-$18M
Q4 22	$11M	$7M	-$44M
Q1 23	$8M	$7M	-$22M
Q2 23	$9M	$7M	-$23M
Q3 23	$15M	$14M	-$14M
Q4 23	$14M	$13M	-$16M
Q1 24	$12M	$11M	-$33M
Q2 24	$9M	$8M	-$35M
Q3 24	$11M	$10M	-$33M
Q4 24	$12M	$11M	-$45M
Q1 25	$24M	$24M	-$49M
Q2 25	$5M	$5M	-$62M
Q3 25	$966.0K	$245.0K	-$62M
Q4 25	$620.0K	$245.0K	-$70M

Valuation

Quarter	P/S	P/E
Q1 22	29.6x	—
Q2 22	27.8x	—
Q3 22	27.2x	—
Q4 22	27.8x	—
Q1 23	29.0x	—
Q2 23	30.9x	—
Q3 23	27.1x	—
Q4 23	25.0x	—
Q1 24	23.0x	—
Q2 24	22.9x	—
Q3 24	25.2x	—
Q4 24	26.6x	—
Q1 25	20.6x	—
Q2 25	22.2x	—
Q3 25	27.2x	—
Q4 25	36.7x	—

Operating Cash Flow

Quarter	Operating CF	Free CF
Q1 22	-$20M	-$20M
Q2 22	-$19M	-$19M
Q3 22	-$13M	-$14M
Q4 22	-$13M	-$13M
Q1 23	-$17M	-$17M
Q2 23	$57M	$57M
Q3 23	-$15M	-$17M
Q4 23	-$23M	-$24M
Q1 24	-$31M	-$32M
Q2 24	-$20M	-$21M
Q3 24	-$39M	-$41M
Q4 24	-$36M	-$36M
Q1 25	-$53M	-$53M
Q2 25	-$63M	-$64M
Q3 25	-$59M	-$60M
Q4 25	-$65M	-$66M

Capital Expenditures

Quarter	CapEx
Q1 22	$149.0K
Q2 22	$218.0K
Q3 22	$1M
Q4 22	$585.0K
Q1 23	$484.0K
Q2 23	$396.0K
Q3 23	$2M
Q4 23	$883.0K
Q1 24	$1M
Q2 24	$900.0K
Q3 24	$2M
Q4 24	$384.0K
Q1 25	$276.0K
Q2 25	$1M
Q3 25	$798.0K
Q4 25	$986.0K

CapEx

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q1 22	+26.9%	+51.0%
Q2 22	+28.3%	+54.0%
Q3 22	+10.5%	+16.6%
Q4 22	-8.8%	+83.4%
Q1 23	-17.3%	+6.0%
Q2 23	-21.3%	+3.5%
Q3 23	+51.8%	+4.2%
Q4 23	+33.2%	-44.0%
Q1 24	+52.1%	+53.9%
Q2 24	+4.1%	+38.2%
Q3 24	-30.8%	+46.2%
Q4 24	-17.4%	+87.0%
Q1 25	+109.3%	+62.8%
Q2 25	-43.7%	+53.5%
Q3 25	-90.8%	+45.6%
Q4 25	-94.6%	+24.9%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q1 22	$3M	37.4%
Q2 22	$4M	35.8%
Q3 22	$3M	32.0%
Q4 22	$3M	31.9%
Q1 23	$3M	39.7%
Q2 23	$2M	19.6%
Q3 23	$4M	23.9%
Q4 23	$4M	25.6%
Q1 24	$13M	108.7%
Q2 24	$9M	91.7%
Q3 24	$7M	70.8%
Q4 24	$8M	68.2%
Q1 25	$8M	32.0%
Q2 25	$7M	128.9%
Q3 25	$6M	665.4%
Q4 25	$7M	1088.5%

OpEx Breakdown

Quarter	R&D	G&A	S&M
Q1 22	$10M	$9M	$7M
Q2 22	$13M	$9M	$7M
Q3 22	$11M	$9M	$6M
Q4 22	$16M	$8M	$6M
Q1 23	$14M	$9M	$6M
Q2 23	$16M	$9M	$5M
Q3 23	$17M	$11M	$479.0K
Q4 23	$18M	$11M	$185.0K
Q1 24	$30M	$14M	$6.0K
Q2 24	$30M	$13M	$50.0K
Q3 24	$30M	$13M	$24.0K
Q4 24	$43M	$13M	$51.0K
Q1 25	$59M	$14M	$35.0K
Q2 25	$55M	$12M	$35.0K
Q3 25	$48M	$14M	$26.0K
Q4 25	$59M	$11M	—

Revenue Segments

Quarter	D E X Y C U Product	Y U T I Q Product	License And Collaboration Agreement	Royalty	Product
Q1 22	$4M	$5M	—	—	—
Q2 22	$4M	$7M	—	—	—
Q3 22	$2M	$7M	—	—	—
Q4 22	$833.0K	$9M	$202.0K	$474.0K	—
Q1 23	—	—	$34.0K	$255.0K	$7M
Q2 23	—	—	$4M	$235.0K	$5M
Q3 23	—	—	$14M	$249.0K	$816.0K
Q1 25	—	$600.0K	$11M	$13M	$715.0K
Q2 25	—	—	$5M	—	—
Q3 25	—	—	$150.0K	$234.0K	$582.0K

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 22	$102M	$89M	$191M
Q2 22	$82M	$89M	$171M
Q3 22	$75M	$82M	$157M
Q4 22	$96M	$49M	$145M
Q1 23	$106M	$17M	$122M
Q2 23	$140M	$3M	$143M
Q3 23	$133M	$3M	$136M
Q4 23	$281M	$50M	$331M
Q1 24	$271M	$28M	$299M
Q2 24	$91M	$189M	$280M
Q3 24	$80M	$174M	$254M
Q4 24	$100M	$271M	$371M
Q1 25	$85M	$233M	$318M
Q2 25	$71M	$185M	$256M
Q3 25	$75M	$129M	$204M
Q4 25	$102M	$204M	$306M

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q1 22	37M	+13.9%	+50.6%
Q2 22	37M	+0.2%	+29.8%
Q3 22	37M	+0.0%	+29.8%
Q4 22	37M	+0.0%	+14.2%
Q1 23	37M	+0.4%	+0.6%
Q2 23	38M	+0.2%	+0.7%
Q3 23	38M	+2.0%	+2.7%
Q4 23	42M	+10.0%	+12.9%
Q1 24	53M	+25.5%	+41.2%
Q2 24	53M	+0.6%	+41.6%
Q3 24	54M	+2.3%	+42.0%
Q4 24	65M	+18.6%	+53.1%
Q1 25	70M	+8.1%	+31.9%
Q2 25	70M	+0.2%	+31.4%
Q3 25	70M	+0.3%	+28.9%
Q4 25	83M	+18.3%	+28.6%

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q1 22	$75.6K	123
Q2 22	$94.0K	123
Q3 22	$81.4K	123
Q4 22	$73.1K	144
Q1 23	$53.4K	144
Q2 23	$63.2K	144
Q3 23	$105.6K	144
Q4 23	$115.9K	121
Q1 24	$96.6K	121
Q2 24	$78.3K	121
Q3 24	$87.0K	121
Q4 24	$70.2K	165
Q1 25	$148.2K	165
Q2 25	$32.3K	165
Q3 25	$5.9K	165
Q4 25	$2.9K	214

Revenue / Employee